The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Implementing machine learning to improve MDS prognostication
Adrian Mosquera Orgueira, MD, PhD, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Spain, comments on the development of a machine learning (ML) model to improve prognostication in myelodysplastic syndromes (MDS). Using readily accessible data from a large cohort of patients, researchers developed a machine learning model and found that it was better at prognostication than the Revised International Prognostic Scoring System (IPSS-R), with some data suggesting that this model performs similarly to systems incorporating genomics. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche, Amgen, AstraZeneca, Janssen, Abbvie, Takeda, Brystol, GSK, Pfizer,: Consultancy, Honoraria, Research Funding.
